Delcath Systems, Inc. Announces Positive Phase 3 FOCUS Trial Results for Hepzato(TM) in Liver-Dominant Metastatic Ocular Melanoma, Including Initial Survival Data Analysis

Stock Information for ARCA biopharma Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About ARCA biopharma Inc.

Delcath Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Delcath Systems Reports Fourth Quarter and Full Year 2023 Results and Provides Business Update
Delcath Systems Closes $7 Million Private Placement
Delcath Systems to Host Fourth Quarter and Full Year 2023 Results and Business Update Call
Delcath Systems Appoints Martha S. Rook as Chief Operating Officer
Delcath Systems Announces $7 Million Private Placement
Delcath Systems Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Delcath Systems to Participate in Upcoming Investor Conferences

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.